Key Congenital Adrenal Hyperplasia Therapies: EFMODY (Hydrocortisone Modified-release Hard Capsules), Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631 ...

The company’s portfolio expanded significantly in late 2024 with the approval of Crenessity (crinecerfont) for adult and pediatric patients with classic CAH.

Barron’s: PGIM Investments ranked 4 out of 48, 8 out of 47, 12 out of 46 firms for the 1-, 5-, and 10-year periods ended 12/31/2024, respectively. See back page for methodology which takes into ...

In May 2025, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has released new findings from its Phase 3 CAHtalyst™ Adult and Pediatric trials evaluating CRENESSITY™ (crinecerfont).

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, finds itself at a pivotal juncture. According ...

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, finds itself at a pivotal juncture. According ...

Alfuzosin does not appear to interact with warfarin, digoxin, hydrochlorothiazide, or atenolol. [23, 81] Caution is recommended when alfuzosin is given to patients taking other antihypertensives ...